PURPOSE: Autocrine expression of interleukin (IL)-6 by transitional cell carcinoma (TCC) in response to bacillus Calmette-Guerin (BCG) may have an important role in promoting BCG adherence to TCC and consequently in BCG treatment efficacy. IL-6 expression in response to BCG requires nuclear factor (NF)-kappaB mediated signal transduction. We evaluated the influence of androgens on BCG induced, NF-kappaB mediated IL-6 expression. MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction was used to confirm androgen receptor expression in the human TCC lines 253J and T24. A reporter construct containing an androgen response element was used to establish the integrity of androgen mediated signal transduction. Subsequently the dose dependent effect of dihydrotestosterone (DHT) on BCG induced IL-6 expression and NF-kappaB signaling was evaluated. Two pharmacological androgen receptor blockers were used to determine if receptor blockade inhibited the effect of DHT on activation of the androgen response element, NF-kappaB signaling and BCG induced IL-6 expression. RESULTS: The 2 human TCC lines expressed androgen receptor and demonstrated intact androgen stimulated signaling pathways. DHT suppressed BCG induced, NF-kappaB mediated signaling and IL-6 expression in a dose dependent manner. DHT decreased mRNA levels of IL-6, expression of the full-length IL-6 promoter construct and expression of an NF-kappaB specific reporter construct in response to BCG relative to controls. Competitive pharmacological blockade of androgen receptor inhibited the effect of DHT on BCG induced signaling in dose dependent fashion. CONCLUSIONS: DHT down-regulates NF-kappaB mediated IL-6 expression by human TCC lines in response to BCG. This effect depends on a functional androgen receptor signaling pathway and it can be blocked by the inhibition of androgen/androgen receptor binding.
PURPOSE: Autocrine expression of interleukin (IL)-6 by transitional cell carcinoma (TCC) in response to bacillus Calmette-Guerin (BCG) may have an important role in promoting BCG adherence to TCC and consequently in BCG treatment efficacy. IL-6 expression in response to BCG requires nuclear factor (NF)-kappaB mediated signal transduction. We evaluated the influence of androgens on BCG induced, NF-kappaB mediated IL-6 expression. MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction was used to confirm androgen receptor expression in the human TCC lines 253J and T24. A reporter construct containing an androgen response element was used to establish the integrity of androgen mediated signal transduction. Subsequently the dose dependent effect of dihydrotestosterone (DHT) on BCG induced IL-6 expression and NF-kappaB signaling was evaluated. Two pharmacological androgen receptor blockers were used to determine if receptor blockade inhibited the effect of DHT on activation of the androgen response element, NF-kappaB signaling and BCG induced IL-6 expression. RESULTS: The 2 human TCC lines expressed androgen receptor and demonstrated intact androgen stimulated signaling pathways. DHT suppressed BCG induced, NF-kappaB mediated signaling and IL-6 expression in a dose dependent manner. DHT decreased mRNA levels of IL-6, expression of the full-length IL-6 promoter construct and expression of an NF-kappaB specific reporter construct in response to BCG relative to controls. Competitive pharmacological blockade of androgen receptor inhibited the effect of DHT on BCG induced signaling in dose dependent fashion. CONCLUSIONS:DHT down-regulates NF-kappaB mediated IL-6 expression by human TCC lines in response to BCG. This effect depends on a functional androgen receptor signaling pathway and it can be blocked by the inhibition of androgen/androgen receptor binding.
Authors: Harun Fajkovic; Joshua A Halpern; Eugene K Cha; Atessa Bahadori; Thomas F Chromecki; Pierre I Karakiewicz; Eckart Breinl; Axel S Merseburger; Shahrokh F Shariat Journal: World J Urol Date: 2011-06-09 Impact factor: 4.226
Authors: Francesca Sanguedolce; Luigi Cormio; Giuseppe Carrieri; Beppe Calò; Davide Russo; Andrea Menin; Antonio Luigi Pastore; Francesco Greco; Giorgio Bozzini; Antonio Galfano; Giovannalberto Pini; Angelo Porreca; Filippo Mugavero; Mario Falsaperla; Carlo Ceruti; Luca Cindolo; Alessandro Antonelli; Andrea Minervini Journal: Histol Histopathol Date: 2019-12-05 Impact factor: 2.303
Authors: Magaly Martinez-Ferrer; Juan M Iturregui; Consolate Uwamariya; Jonathan Starkman; Ali-Reza Sharif-Afshar; Kichiya Suzuki; Wit Visedsindh; Robert J Matusik; Roger R Dmochowski; Neil A Bhowmick Journal: Am J Pathol Date: 2007-12-13 Impact factor: 4.307
Authors: Stephen A Boorjian; Hannelore V Heemers; Igor Frank; Sara A Farmer; Lucy J Schmidt; Thomas J Sebo; Donald J Tindall Journal: Endocr Relat Cancer Date: 2008-10-09 Impact factor: 5.678
Authors: Shahrokh F Shariat; John P Sfakianos; Michael J Droller; Pierre I Karakiewicz; Siegfried Meryn; Bernard H Bochner Journal: BJU Int Date: 2009-11-13 Impact factor: 5.588